Lung Cancer Management最新文献_第5页

Stereotactic ablative body radiotherapy versus conventionally fractionated radiotherapy for early stage large cell neuroendocrine carcinoma of the lung. 立体定向消融体放疗对早期肺大细胞神经内分泌癌的分级放疗比较。

IF 2.8

Lung Cancer Management Pub Date : 2020-04-21 DOI: 10.2217/lmt-2020-0004

Rodney E Wegner, Stephen Abel, Athanasios Colonias

引用次数: 4

Welcome to Volume 9 of Lung Cancer Management. 欢迎来到《肺癌管理》第九卷。

IF 2.8

Lung Cancer Management Pub Date : 2020-03-24 DOI: 10.2217/lmt-2020-0007

Katherine Gordon

引用次数: 1

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC. EGFR突变阳性NSCLC从第一代或第二代EGFR- tki切换到奥西替尼。

IF 2.8

Lung Cancer Management Pub Date : 2020-03-19 DOI: 10.2217/lmt-2020-0005

Fumio Imamura, Takako Inoue, Kei Kunimasa, Aki Kubota, Hanako Kuhara, Motohiro Tamiya, Kazumi Nishino, Madoka Kimura, Kika Kuno, Hayato Kawachi, Toru Kumagai

引用次数: 4

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib. 晚期ALK+ NSCLC患者脑转移治疗的成本分析:阿勒替尼与克唑替尼

IF 2.8

Lung Cancer Management Pub Date : 2020-03-04 DOI: 10.2217/lmt-2019-0011

Dolores Isla, Bartomeu Massuti, Martín Lázaro, Lucía Ruiz de Alda, Rocio Gordo, Nuria Ortega-Joaquín, Itziar Oyagüez

{"title":"Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib.","authors":"Dolores Isla, Bartomeu Massuti, Martín Lázaro, Lucía Ruiz de Alda, Rocio Gordo, Nuria Ortega-Joaquín, Itziar Oyagüez","doi":"10.2217/lmt-2019-0011","DOIUrl":"https://doi.org/10.2217/lmt-2019-0011","url":null,"abstract":"Aim: To estimate management cost of NSCLC ALK+ patients with and without brain metastasis (BM), and to compare annual costs in patients treated with alectinib or crizotinib.Methods: Management cost/year (€ 2018) in patients with and without BM was estimated with disaggregated resource consumption provided by local oncologists, including medical visits, hospitalizations, diagnostic/laboratory tests, imaging techniques and surgical procedures. The comparison of costs/year with alectinib and crizotinib, considered the cumulative 12-month incidence of BM in ALEX trial (9.4 and 41.4%, respectively).Results: Management cost was €6173.42/patient-year without BM and €21,637.50/patient-year with BM. With alectinib, average cost/patient was lower than crizotinib (€4948.51/patient-year).Conclusion: Prevention of BM with alectinib may result in reductions of cost/year in the management of advanced ALK+ NSCLC.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2020-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37808521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Risk of brain metastases in T1-3N0 NSCLC: a population-based analysis. T1-3N0 NSCLC脑转移风险:基于人群的分析

IF 2.8

Lung Cancer Management Pub Date : 2020-02-25 DOI: 10.2217/lmt-2019-0010

Michael T Milano, James E Bates, Justin Budnik, Haoming Qiu, Sara Hardy, Michael A Cummings, Megan A Baumgart, Ronald J Maggiore, Deborah A Mulford, Kenneth Y Usuki

{"title":"Risk of brain metastases in T1-3N0 NSCLC: a population-based analysis.","authors":"Michael T Milano, James E Bates, Justin Budnik, Haoming Qiu, Sara Hardy, Michael A Cummings, Megan A Baumgart, Ronald J Maggiore, Deborah A Mulford, Kenneth Y Usuki","doi":"10.2217/lmt-2019-0010","DOIUrl":"https://doi.org/10.2217/lmt-2019-0010","url":null,"abstract":"Aim: Several consensus guidelines recommend against routine brain imaging at diagnosis of T1-3N0 non-small cell lung cancer (NSCLC).Methods: From the Surveillance, Epidemiology and End Results registry, patients with pathologically confirmed T1-3N0 NSCLC were identified. Risks of brain metastases at time of initial diagnosis were analyzed.Results: Patients selected to not undergo primary NSCLC resection had approximately tenfold greater incidence of brain metastases versus those who did. Younger age, adenocarcinoma histology, higher tumor stage and higher histologic grade were all significantly (p < 0.0001) associated with greater likelihood of presenting with brain metastases.Conclusion: Given the morbidity and mortality of brain metastases, routine brain screening after NSCLC diagnosis (particularly adenocarcinoma) may be justifiable, though more refined cost-benefit analyses are warranted.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2020-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37808519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer. 晚期非小细胞肺癌患者BMI与免疫检查点抑制剂应答的相关性研究

IF 2.8

Lung Cancer Management Pub Date : 2020-02-25 DOI: 10.2217/lmt-2019-0016

Alain Gelibter, Mario Occhipinti, Simona Pisegna, Alessio Cortellini, Enrico Cortesi, Paolo Marchetti

引用次数: 9

Optimizing molecular residual disease detection using liquid biopsy postoperatively in early stage lung cancer. 早期肺癌术后液体活检分子残留检测优化

IF 2.8

Lung Cancer Management Pub Date : 2020-02-21 DOI: 10.2217/lmt-2019-0017

Anna L McGuire, Curtis B Hughesman, Melissa K McConechy, Barb Melosky, Stephen Lam, Renelle Myers, John Yee, Ernest Tang, Stephen Yip

引用次数: 2

Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach? 化疗和/或免疫检查点抑制剂在非小细胞肺癌一线:什么是最好的方法?

IF 2.8

Lung Cancer Management Pub Date : 2020-02-12 DOI: 10.2217/lmt-2019-0018

Luigi Della Gravara, Ciro Battiloro, Rosa Cantile, Antonietta Letizia, Fabiana Vitiello, Vincenzo Montesarchio, Danilo Rocco

引用次数: 15

Practical challenges in patients with stage III NSCLC receiving checkpoint inhibitors after chemoradiation. 化疗后接受检查点抑制剂的III期非小细胞肺癌患者的实际挑战。

IF 2.8

Lung Cancer Management Pub Date : 2020-02-06 DOI: 10.2217/lmt-2020-0001

Nikhil A Shukla, Nasser H Hanna

{"title":"Practical challenges in patients with stage III NSCLC receiving checkpoint inhibitors after chemoradiation.","authors":"Nikhil A Shukla, Nasser H Hanna","doi":"10.2217/lmt-2020-0001","DOIUrl":"https://doi.org/10.2217/lmt-2020-0001","url":null,"abstract":"NSCLC accounts for 80% of all lung cancer diagnoses, and approximately a third of patients present with locally advanced (stage III) disease [1]. The optimal therapy for fit patients with unresectable and/or inoperable stage III disease has evolved over the last three decades from radiation alone to sequential chemoradiation (CRT) to concurrent CRT followed by checkpoint inhibitor therapy (CPI). The recently reported PACIFIC trial generated a paradigm shift in the treatment of such patients, with a 3-year overall survival (OS) of 57% for patients receiving consolidation durvalumab compared with 43.5% for those receiving placebo [2–4]. Similar outcomes were reported with consolidation pembrolizumab in a Hoosier Cancer Research Network (HCRN) Phase II Trial [5]. In this article, we explore key clinical challenges that arise when treating patients with consolidation CPI after CRT for patients with stage III NSCLC; namely, the management of CPI-related pneumonitis, timing of consolidation CPI and their role in patients with PD-L1 TPS <1% and distinguishing local progression versus pseudoprogression.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2020-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37808518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Convex endobronchial ultrasound: same coin, two faces. Challenging biopsy and staging for non-small-cell lung cancer. 支气管内凸超声:同一枚硬币，两面。非小细胞肺癌具有挑战性的活检和分期。

IF 2.8

Lung Cancer Management Pub Date : 2020-01-16 DOI: 10.2217/lmt-2019-0008

Konstantinos Sapalidis, Konstantinos Romanidis, Panagoula Oikonomou, Paul Zarogoulidis, Athanasios Katsaounis, Aikaterini Amaniti, Nikolaos Michalopoulos, Charilaos Koulouris, Kosmas Tsakiridis, Dimitrios Giannakidis, Isaak Kesisoglou, Aris Ioannidis, Iason Nikolaos-Katsios, Anastasios Vagionas, Wolfgang Hohenforst-Schmidt, Haidong Huang, Chong Bai, Alexandru Marian Goganau, Christoforos Kosmidis

{"title":"Convex endobronchial ultrasound: same coin, two faces. Challenging biopsy and staging for non-small-cell lung cancer.","authors":"Konstantinos Sapalidis, Konstantinos Romanidis, Panagoula Oikonomou, Paul Zarogoulidis, Athanasios Katsaounis, Aikaterini Amaniti, Nikolaos Michalopoulos, Charilaos Koulouris, Kosmas Tsakiridis, Dimitrios Giannakidis, Isaak Kesisoglou, Aris Ioannidis, Iason Nikolaos-Katsios, Anastasios Vagionas, Wolfgang Hohenforst-Schmidt, Haidong Huang, Chong Bai, Alexandru Marian Goganau, Christoforos Kosmidis","doi":"10.2217/lmt-2019-0008","DOIUrl":"https://doi.org/10.2217/lmt-2019-0008","url":null,"abstract":"Lung cancer is still diagnosed at a late stage due to lack of early disease symptoms. Despite the development of new diagnostic endoscopic tools, such as radial/convex endobronchial ultrasounds (EBUS) and electromagnetic navigation, most patients are still diagnosed at advanced stage disease. Most of the patients refer to their doctor only if they cough blood or their cough changes character. There are challenging cases in the diagnosis and staging of a patient, such as the one that we will present. We present a case of lung cancer that was diagnosed through a biopsy from the main lesion, with access from the esophagus, through transbronchial needle aspiration with EBUS, under general anesthesia and intubation. Staging with transbronchial needle aspiration with EBUS was also performed at the same session.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2020-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37581115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5